-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
Biomarin Pharmaceutical Inc quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from 2010 to 2023.
- Biomarin Pharmaceutical Inc Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2024 was $285 K.
- Biomarin Pharmaceutical Inc annual Deferred Income Tax Expense (Benefit) for 2023 was -$45 M, a 13.6% increase from 2022.
- Biomarin Pharmaceutical Inc annual Deferred Income Tax Expense (Benefit) for 2022 was -$52.1 M, a 234% decline from 2021.
- Biomarin Pharmaceutical Inc annual Deferred Income Tax Expense (Benefit) for 2021 was -$15.6 M, a 98.2% increase from 2020.
Deferred Income Tax Expense (Benefit), Trailing 12 Months (USD)
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)